| Mutation in TET2 in Myeloid Cancers F Delhommeau, S Dupont, VD Valle, C James, S Trannoy, A Massé, ... New England Journal of Medicine 360 (22), 2289-2301, 2009 | 2237 | 2009 |
| Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 A Silvin, N Chapuis, G Dunsmore, AG Goubet, A Dubuisson, L Derosa, ... Cell 182 (6), 1401-1418. e18, 2020 | 824 | 2020 |
| Prognostic score including gene mutations in chronic myelomonocytic leukemia R Itzykson, O Kosmider, A Renneville, V Gelsi-Boyer, M Meggendorfer, ... Journal of clinical oncology 31 (19), 2428-2436, 2013 | 609 | 2013 |
| Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias R Itzykson, O Kosmider, T Cluzeau, MD Mas, F Dreyfus, O Beyne-Rauzy, ... Leukemia 25 (7), 1147-1152, 2011 | 586 | 2011 |
| Molecular international prognostic scoring system for myelodysplastic syndromes E Bernard, H Tuechler, PL Greenberg, RP Hasserjian, JE Arango Ossa, ... NEJM evidence 1 (7), EVIDoa2200008, 2022 | 579 | 2022 |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 26 (10), 1549-1556, 2020 | 557 | 2020 |
| TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) O Kosmider, V Gelsi-Boyer, M Cheok, S Grabar, V Della-Valle, F Picard, ... Blood, The Journal of the American Society of Hematology 114 (15), 3285-3291, 2009 | 369 | 2009 |
| Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia L Willems, N Jacque, A Jacquel, N Neveux, T Trovati Maciel, M Lambert, ... Blood, The Journal of the American Society of Hematology 122 (20), 3521-3532, 2013 | 346 | 2013 |
| Clonal architecture of chronic myelomonocytic leukemias R Itzykson, O Kosmider, A Renneville, M Morabito, C Preudhomme, ... Blood, The Journal of the American Society of Hematology 121 (12), 2186-2198, 2013 | 313 | 2013 |
| Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients S Georgin‐Lavialle, B Terrier, AF Guedon, M Heiblig, T Comont, E Lazaro, ... British Journal of Dermatology 186 (3), 564-574, 2022 | 306 | 2022 |
| Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes F Damm, O Kosmider, V Gelsi-Boyer, A Renneville, N Carbuccia, ... Blood, The Journal of the American Society of Hematology 119 (14), 3211-3218, 2012 | 298 | 2012 |
| Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms O Kosmider, V Gelsi-Boyer, L Slama, F Dreyfus, O Beyne-Rauzy, ... Leukemia 24 (5), 1094-1096, 2010 | 298 | 2010 |
| ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients MM Patnaik, R Itzykson, TL Lasho, O Kosmider, CM Finke, CA Hanson, ... Leukemia 28 (11), 2206-2212, 2014 | 297 | 2014 |
| TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia O Kosmider, V Gelsi-Boyer, M Ciudad, C Racoeur, V Jooste, N Vey, ... Haematologica 94 (12), 1676, 2009 | 285 | 2009 |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups D Haase, KE Stevenson, D Neuberg, JP Maciejewski, A Nazha, ... Leukemia 33 (7), 1747-1758, 2019 | 256 | 2019 |
| BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders F Damm, V Chesnais, Y Nagata, K Yoshida, L Scourzic, Y Okuno, ... Blood, The Journal of the American Society of Hematology 122 (18), 3169-3177, 2013 | 233 | 2013 |
| Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission O Nibourel, O Kosmider, M Cheok, N Boissel, A Renneville, N Philippe, ... Blood, The Journal of the American Society of Hematology 116 (7), 1132-1135, 2010 | 180 | 2010 |
| Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a M ayo C linic‐F rench C onsortium S tudy EA Wassie, R Itzykson, TL Lasho, O Kosmider, CM Finke, CA Hanson, ... American journal of hematology 89 (12), 1111-1115, 2014 | 156 | 2014 |
| Azacitidine for patients with vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry T Comont, M Heiblig, E Rivière, L Terriou, J Rossignol, D Bouscary, ... British journal of haematology 196 (4), 969-974, 2022 | 146 | 2022 |
| APR-246 induces early cell death by ferroptosis in acute myeloid leukemia R Birsen, C Larrue, J Decroocq, N Johnson, N Guiraud, M Gotanegre, ... Haematologica 107 (2), 403, 2021 | 145 | 2021 |
